Default Rate

Strong glaucoma sales and disciplined spending helped Iridex narrow its quarterly loss, signaling resilience despite retina segment woes and global headwinds.

A $290M war chest fuels a new public biotech aiming to help millions of migraine patients who don't respond to current blockbuster therapies.

A new AI trading bot promises hands-free profits, but a lack of regulatory oversight and performance data raises critical questions for new investors.

A Yale spinout's AI-powered EEG platform promises to prevent birth injuries and cut C-sections by monitoring the fetal brain, not just heart rate.

As Sri Lanka emerges from its economic crisis, a first-of-its-kind European-regulated fund provides a liquid, secure path to its undervalued assets.

A critical vulnerability in the OpenClaw AI agent allowed any website to silently hijack developer tools, exposing a new and dangerous class of security risks.

Following a devastating school shooting, a national mental health provider offers a free crisis line, highlighting the urgent need for trauma support.